High-Risk Drug Monitoring · Horwich

High-Risk Drug Monitoring in Horwich.

Systematic monitoring of DOACs, lithium, methotrexate, amiodarone and other high-risk drugs — to ICB-specified intervals and audit-ready evidence. Delivered to Horwich PCNs and GP practices from the BCS Halifax (West Yorkshire) hub — with paired cover from our Chiswick (West London) hub. BCS is the only UK provider operating this dual-hub clinical pharmacy model.

Dual-hub delivery

The only UK provider with a Yorkshire + London hub.

Every high-risk drug monitoring placement in Horwich is mobilised from one of our two clinical hubs — Halifax (West Yorkshire) as the lead and Chiswick (West London) as paired cover. The dual-hub model is unique to BCS: no other clinical pharmacy provider in the UK runs Northern and Southern hubs with shared SOPs, shared supervision and same-week cross-cover. That is what guarantees continuity of high-risk drug monitoring for a Horwich PCN through sickness, leave and turnover.

  • Lead delivery from the BCS Halifax (West Yorkshire) hub
  • Paired cover from BCS Chiswick (West London) — same SOPs, same supervision
  • Same-week sickness, leave and maternity cover guaranteed
  • ARRS-compliant, GPhC-registered, IP-qualified workforce
  • One SLA, one report, one escalation point

Horwich · local context

Horwich PCNs sit within the local North West ICB (Greater Manchester, Cheshire and Merseyside, or Lancashire and South Cumbria).

Horwich PCNs work close to a named North West acute trust on discharge reconciliation, which BCS technicians close inside the IIF reporting window.

What you get

What high-risk drug monitoring in Horwich actually looks like.

  • DOAC review and renal function tracking
  • Lithium, methotrexate, amiodarone monitoring
  • Recall and chase workflow
  • Missed monitoring escalation
  • Closed-loop audit evidence

Horwich · what good looks like

Typical first-year markers.

4–6 wks
Mobilisation in Horwich
2 hubs
Halifax + Chiswick — unique to BCS
100%
Supervision evidenced for audit
Monthly
QA-checked outcomes report

Why Horwich PCNs choose BCS for high-risk drug monitoring.

Solo recruitment for high-risk drug monitoring in Horwich leaves a network exposed to sickness, maternity and retention risk, and rarely meets the supervision standard ICBs now ask for. BCS removes all of that — pharmacists are part of a clinical team, supervision is built in, and continuity is guaranteed by the Halifax (West Yorkshire)/Chiswick (West London) dual-hub.

Whether you are a single Horwich PCN starting your first high-risk drug monitoring programme, or a federation coordinating high-risk drug monitoring across multiple North West networks, the BCS managed model scales without changing your contract.

Frequently asked questions — High-Risk Drug Monitoring in Horwich.

What proportion of patients are typically overdue?+

First sweeps typically find 15-25% of high-risk drug patients overdue for monitoring.

Does BCS already deliver high-risk drug monitoring in Horwich?+

BCS supports PCNs and GP practices across North West from our Halifax (West Yorkshire) hub with paired cover from Chiswick (West London), and is actively delivering or available to mobilise high-risk drug monitoring in Horwich. Get in touch and we'll confirm current capacity.

What makes the dual-hub model different?+

BCS is the only UK clinical pharmacy provider running both a Northern (Halifax) and Southern (Chiswick) hub. That means same-week cross-cover, one SOP set across the country, and no service gap when staff are off — something single-hub or single-region providers cannot match.

How quickly can BCS mobilise high-risk drug monitoring in Horwich?+

In most cases BCS mobilises high-risk drug monitoring for a Horwich PCN within 4 to 6 weeks of contract sign-off, with remote prescribing back-up available from the hub sooner if needed.

Talk to our Service Development team

30-minute discovery call. We'll show you how BCS maps to your PCN's specific priorities.

Book a discovery call